SCHEMBL6475563

SCHEMBL6475563

Nc1ccc(CCc2ccc(Nc3ccccc3C(=O)O)cc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 4/20 0.69
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
BLM P54132 2/20 0.67
RECQL P46063 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
FABP4 P15090 1/20 0.59
PTGS1 P23219 1/20 0.55
AKR1C3 P42330 1/20 0.55
AKR1C2 P52895 1/20 0.55
MAPT P10636 2/20 0.51
MT-CO2 P00403 2/20 0.51
ALDH1A1 P00352 1/20 0.51
TEAD4 Q15561 1/20 0.51
HCAR2 Q8TDS4 2/20 0.50
MAOA P21397 2/20 0.49
MAOB P27338 2/20 0.49
CDC25B P30305 1/20 0.48
TTR P02766 1/20 0.48
KDM4E B2RXH2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6474416 0.94 SIRT2 (0.62) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL6475772 0.92 MEN1 (0.76) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL6482855 0.91 SIRT2 (0.77) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL29740645 0.91 FABP4 (0.71) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL2128794 0.91 FABP4 (0.71) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL6475626 0.88 MEN1 (0.67) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL6475355 0.87 MEN1 (0.69) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL13855746 0.84 MEN1 (0.65) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL6474093 0.83 MEN1 (0.61) SIRT2MEN1KMT2ABLMRECQL
SCHEMBL6480207 0.83 SIRT2 (0.66) SIRT2MEN1KMT2ABLMRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
CN-1378446-A Method for inhibiting amyloid aggregation and imaging amyloid deposits WARNER LAMBERT CO (US) 2002-11-06 CN disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 SIRT2 2735/4885MEN1 474/4885KMT2A 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.